Financials Tharimmune, Inc.

Equities

THAR

US4327052001

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-05-15 pm EDT 5-day change 1st Jan Change
0.3614 USD -0.88% Intraday chart for Tharimmune, Inc. -11.75% -29.00%

Valuation

Fiscal Period: December 2023 2024 2025
Capitalization 1 1.285 4.297 -
Enterprise Value (EV) 1 1.285 4.297 4.297
P/E ratio -0.07 x - -
Yield - - -
Capitalization / Revenue - - -
EV / Revenue - - -
EV / EBITDA - - -
EV / FCF - - -
FCF Yield - - -
Price to Book - - -
Nbr of stocks (in thousands) 2,525 11,786 -
Reference price 2 0.5090 0.3614 0.3614
Announcement Date 2/23/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2023 2024 2025
Net sales 1 - - - -
EBITDA - - - -
EBIT 1 - - -12 -14.5
Operating Margin - - - -
Earnings before Tax (EBT) - - - -
Net income -2.207 -9.319 - -
Net margin - - - -
EPS -8.750 -7.140 - -
Free Cash Flow - - - -
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 4/1/22 2/23/24 - -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2023 2024 2025
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - - -
ROE (net income / shareholders' equity) - - - -
ROA (Net income/ Total Assets) - - - -
Assets - - - -
Book Value Per Share - - - -
Cash Flow per Share - - - -
Capex - - - -
Capex / Sales - - - -
Announcement Date 4/1/22 2/23/24 - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3614 USD
Average target price
5 USD
Spread / Average Target
+1,283.51%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. THAR Stock
  4. Financials Tharimmune, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW